1629992-28-4
1629992-28-4
Chemical Structure
DH20931
- CAS No.: 1629992-28-4
- Formula:C21H21ClN2O2
- Molecular Weight:368.86
InChIKey: JVGUFPVWKWESKD-UHFFFAOYSA-M
SMILES: COC1=CC=C2C3=C4C5=C(CCN4C=[N+]3CCC2=C1)C=C(C=C5)OC.[Cl-]
Biological Activity: DH20931 is a ceramide synthase 2 (CerS2) activator. DH20931 inhibits growth of cancer cells by inducing lipotoxic endoplasmic reticulum (ER) stress. DH20931 shows synergistic anti-tumor efficacy with Doxorubicin (HY-15142A). DH20931 can be used for the research of breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DH20931 | DH20931 is a ceramide synthase 2 (CerS2) activator. DH20931 inhibits growth of cancer cells by inducing lipotoxic endoplasmic reticulum (ER) stress. DH20931 shows synergistic anti-tumor efficacy with Doxorubicin (HY-15142A). DH20931 can be used for the research of breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jaiswal AS, et al. Anti-tumor activity of novel biisoquinoline derivatives against breast cancers. Bioorg Med Chem Lett. 2014;24(20):4850-4853. [Content Brief]
- [2]. Alatawi H, et al. A novel CerS2 activator, DH20931, synergizes with doxorubicin to overcome therapeutic resistance in breast cancer[J]. Cancer Research, 2026, 86(7_Supplement): 4457-4457.
Keywords
